{"id":44579,"date":"2023-12-28T12:37:53","date_gmt":"2023-12-28T12:37:53","guid":{"rendered":"https:\/?p=44579"},"modified":"2023-12-28T12:37:53","modified_gmt":"2023-12-28T12:37:53","slug":"cytokinetics-stock-surges-on-promising-phase-2-trial-results","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/","title":{"rendered":"Cytokinetics Stock Surges on Promising Phase 2 Trial Results"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Cytokinetics Inc&#8217;s stock (<strong><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CYTK\">CYTK: NSD<\/a><\/strong>) surged by over 30% after positive Phase 2 trial results of its lead drug candidate, omecamtiv mecarbil, for treating HFpEF. This indicates investors&#8217; growing confidence in Cytokinetics&#8217;s innovative approach to treating the condition.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CYTK\" target=\"_blank\" rel=\"noopener\">CYTK Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"CYTK\" data-theme=\"wt_bg_trans\" data-uid=\"228624816658d6bd2f1650658d6bd2f1652\" data-width=\"696\" >\n\t\t<\/script><\/p>\n<\/div>\n<p><!-- STA Widget END --><\/p>\n<h2><strong>Stock Target Advisor\u2019s Analysis on Cytokinetics:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Stock Target Advisor&#8217;s stock rating for Cytokinetics Inc (<\/span><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CYTK\"><span style=\"font-weight: 400;\"><strong>CYTK: NSD<\/strong>)<\/span><\/a><span style=\"font-weight: 400;\"> is Sell, their Target Price stands at 66.55, outlining a projected price change of -20.25% over the upcoming 12 months.\u00a0<\/span><span style=\"font-weight: 400;\">Interestingly, Cytokinetics\u00a0Inc<\/span><span style=\"font-weight: 400;\">&#8216;s average analyst rating is Strong Buy. Nevertheless, Stock Target Advisor\u2019s stock analysis of Cytokinetics Inc (<\/span><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CYTK\"><span style=\"font-weight: 400;\"><strong>CYTK: NSD<\/strong><\/span><\/a><span style=\"font-weight: 400;\">) is Slightly Bearish, a forecast based on the balance of 3 positive signals and 5 negative signals.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Cytokinetics Financial Performance:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Looking into <\/span><span style=\"font-weight: 400;\">Cytokinetics&#8217;<\/span><span style=\"font-weight: 400;\"> financial performance, their 1-year capital gain and total return have been exceptional, landing at 82.98%. Over the past week alone, <\/span><span style=\"font-weight: 400;\">Cytokinetics&#8217;<\/span><span style=\"font-weight: 400;\"> (<\/span><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CYTK\"><span style=\"font-weight: 400;\">CYTK: NSD<\/span><\/a><span style=\"font-weight: 400;\">) stock price has increased by +47.72% and has also risen by +51.61% over the past month.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Eyeing the company\u2019s 5-year growth, we note a substantial 607.57% increase in revenue. However, the similar period has also seen a disappointing slide in earnings growth, which stands at -215.01%.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">When we evaluate profitability ratios and valuation, <\/span><span style=\"font-weight: 400;\">Cytokinetics&#8217;<\/span><span style=\"font-weight: 400;\"> Return on Assets is -34.12%, while its Return on Equity stands at a staggering -572.15%. Despite this, their Price to Earnings Ratio is 450, suggesting investors&#8217; optimistic stance on the stock.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Despite <\/span><span style=\"font-weight: 400;\">Cytokinetics&#8217;<\/span><span style=\"font-weight: 400;\"> current beta of 0.57 indicating relatively low volatility, the total count of analysts covering the stock is eight, with an average rating of a Strong Buy, symbolizing high institutional interest.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Conclusion:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Cytokinetics Inc.&#8217;s (<\/span><strong><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CYTK\">CYTK: NSD<\/a><\/strong><span style=\"font-weight: 400;\">) positive Phase 2 trial results for its lead drug candidate, omecamtiv mecarbil, have sparked investor confidence in the potential of the drug and the company&#8217;s innovative approach to treating heart failure with preserved ejection fraction (HFpEF). Although there have been challenges in earnings growth and profitability ratios, the stock&#8217;s high institutional interest and optimistic Price to Earnings Ratio reflect the market&#8217;s positive outlook. Overall, Cytokinetics appears to be in a strong position to continue its growth trajectory in the HFpEF treatment market.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cytokinetics Inc&#8217;s stock (CYTK: NSD) surged by over 30% after positive Phase 2 trial results of its lead drug candidate, omecamtiv mecarbil, for treating HFpEF&#8230;.<\/p>\n","protected":false},"author":17,"featured_media":44581,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-44579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cytokinetics Stock Surges on Promising Phase 2 Trial Results<\/title>\n<meta name=\"description\" content=\"Cytokinetics&#039; stock surges by 30% on positive Phase 2 trial results for its lead drug candidate, omecamtiv mecarbil.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Stock Surges on Promising Phase 2 Trial Results\" \/>\n<meta property=\"og:description\" content=\"Cytokinetics&#039; stock surges by 30% on positive Phase 2 trial results for its lead drug candidate, omecamtiv mecarbil.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-28T12:37:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/12\/Cytokinetics-Stock-Surges-on-Promising-Phase-2-Trial-Results.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Cytokinetics Stock Surges on Promising Phase 2 Trial Results\",\"datePublished\":\"2023-12-28T12:37:53+00:00\",\"dateModified\":\"2023-12-28T12:37:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/\"},\"wordCount\":352,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/\",\"name\":\"Cytokinetics Stock Surges on Promising Phase 2 Trial Results\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2023-12-28T12:37:53+00:00\",\"dateModified\":\"2023-12-28T12:37:53+00:00\",\"description\":\"Cytokinetics' stock surges by 30% on positive Phase 2 trial results for its lead drug candidate, omecamtiv mecarbil.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Stock Surges on Promising Phase 2 Trial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cytokinetics Stock Surges on Promising Phase 2 Trial Results","description":"Cytokinetics' stock surges by 30% on positive Phase 2 trial results for its lead drug candidate, omecamtiv mecarbil.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Stock Surges on Promising Phase 2 Trial Results","og_description":"Cytokinetics' stock surges by 30% on positive Phase 2 trial results for its lead drug candidate, omecamtiv mecarbil.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2023-12-28T12:37:53+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/12\/Cytokinetics-Stock-Surges-on-Promising-Phase-2-Trial-Results.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Cytokinetics Stock Surges on Promising Phase 2 Trial Results","datePublished":"2023-12-28T12:37:53+00:00","dateModified":"2023-12-28T12:37:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/"},"wordCount":352,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/","name":"Cytokinetics Stock Surges on Promising Phase 2 Trial Results","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2023-12-28T12:37:53+00:00","dateModified":"2023-12-28T12:37:53+00:00","description":"Cytokinetics' stock surges by 30% on positive Phase 2 trial results for its lead drug candidate, omecamtiv mecarbil.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/cytokinetics-stock-surges-on-promising-phase-2-trial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Stock Surges on Promising Phase 2 Trial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/44579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=44579"}],"version-history":[{"count":2,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/44579\/revisions"}],"predecessor-version":[{"id":44583,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/44579\/revisions\/44583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/44581"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=44579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=44579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=44579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}